Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Canada.
Fam Cancer. 2009;8(4):563-7. doi: 10.1007/s10689-009-9287-z.
Germ-line mutations in the TP53 gene are rare, but predispose women to a range of cancer types, including early-onset breast cancer. Breast cancers in women from families with the Li-Fraumeni syndrome often occur before age 30. The prevalence of deleterious TP53 mutations in unselected women with early-onset breast cancer is not precisely known. If mutations were found to be sufficiently common, it might be prudent to offer genetic testing to affected women in this age group. We screened the entire TP53 gene in the germ-line DNA from 95 women of various ethnic groups who were diagnosed with breast cancer before age 30, and who had previously been found to be negative for BRCA1 and BRCA2 mutations. No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer.
胚系 TP53 基因突变较为罕见,但可导致女性易患多种癌症类型,包括乳腺癌。Li-Fraumeni 综合征家族中的女性乳腺癌通常发生在 30 岁之前。在无家族癌症史的早发性乳腺癌女性中,有害 TP53 突变的患病率尚不清楚。如果发现突变非常常见,则在该年龄组的受影响女性中进行基因检测可能是谨慎的做法。我们对 95 名不同种族的女性进行了筛查,这些女性在 30 岁之前被诊断出患有乳腺癌,并且之前已被发现 BRCA1 和 BRCA2 突变均为阴性。未发现 TP53 突变。这项研究不支持在没有癌症家族史的情况下,对无选择的早发性乳腺癌女性常规进行 TP53 检测的政策。